Author Correction: Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model

Julia Ludwig^#¹, Stephen W Scally^#^{2

3}, Giulia Costa^#⁴, Sandro Hoffmann¹, Rajagopal Murugan¹, Jana Lossin¹, Katherine Prieto^{2

3}, Anna Obraztsova¹, Nina Lobeto¹, Blandine Franke-Fayard⁵, Chris J Janse⁵, Celia Lebas⁶, Nicolas Collin⁶, Spela Binter⁷, Paul Kellam^{7

8}, Elena A Levashina⁹, Hedda Wardemann¹⁰, Jean-Philippe Julien^{11

12

13}

Affiliations

¹ B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
² Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
³ Department of Immunology, University of Toronto, Toronto, ON, Canada.
⁴ Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
⁵ Malaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
⁶ Vaccine Formulation Institute, Plan-les-Ouates, Switzerland.
⁷ Kymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
⁸ Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.
⁹ Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany. levashina@mpiib-berlin.mpg.de.
¹⁰ B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.wardemann@dkfz.de.
¹¹ Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.
¹² Department of Immunology, University of Toronto, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.
¹³ Department of Biochemistry, University of Toronto, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.

^# Contributed equally.

Published Erratum

Julia Ludwig et al. NPJ Vaccines. 2023.

. 2023 Jun 5;8(1):86.

doi: 10.1038/s41541-023-00687-x.

¹ B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
² Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada.
³ Department of Immunology, University of Toronto, Toronto, ON, Canada.
⁴ Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany.
⁵ Malaria Research Group, Department of Parasitology, Leiden University Medical Center, Leiden, The Netherlands.
⁶ Vaccine Formulation Institute, Plan-les-Ouates, Switzerland.
⁷ Kymab a Sanofi Company, Babraham Research Campus, Cambridge, UK.
⁸ Department of Infectious Diseases, Faculty of Medicine, Imperial College London, London, UK.
⁹ Vector Biology Unit, Max Planck Institute for Infection Biology, Berlin, Germany. levashina@mpiib-berlin.mpg.de.
¹⁰ B Cell Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany. h.wardemann@dkfz.de.
¹¹ Program in Molecular Medicine, The Hospital for Sick Children Research Institute, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.
¹² Department of Immunology, University of Toronto, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.
¹³ Department of Biochemistry, University of Toronto, Toronto, ON, Canada. jean-philippe.julien@sickkids.ca.

^# Contributed equally.

No abstract available

Erratum for

Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
Ludwig J, Scally SW, Costa G, Hoffmann S, Murugan R, Lossin J, Prieto K, Obraztsova A, Lobeto N, Franke-Fayard B, Janse CJ, Lebas C, Collin N, Binter S, Kellam P, Levashina EA, Wardemann H, Julien JP. Ludwig J, et al. NPJ Vaccines. 2023 Apr 7;8(1):52. doi: 10.1038/s41541-023-00653-7. NPJ Vaccines. 2023. PMID: 37029167 Free PMC article.